Vivimed Labs Limited has announced the resignation of its Chief Financial Officer, Mr. Phaninder Nath P S, effective February 06, 2026. The pharmaceutical company informed stock exchanges about this key management change through a regulatory filing under SEBI Listing Obligations and Disclosure Requirements Regulations, 2015.

Resignation Details

The company disclosed that Mr. Phaninder Nath P S tendered his resignation due to personal health issues. In his resignation letter, he mentioned the need to undergo treatment for health problems that have been aggravating over the past few weeks.

Regulatory Compliance

The resignation will result in Mr. Phaninder Nath P S ceasing to be Key Managerial Personnel under Section 203 of the Companies Act, 2013, and Senior Management Personnel under Regulation 30(5) of the SEBI Listing Regulations. This change affects his role in determining materiality of events or transactions for required stock exchange disclosures.

Vivimed Labs has fulfilled its regulatory obligations by notifying both BSE (Code: 532660) and NSE (Symbol: VIVIMEDLAB) about this development. The company provided all required details as per SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024.

Management Transition

In his resignation letter, Mr. Phaninder Nath P S expressed gratitude to the Board for their support and cooperation during his tenure. He wished the company continued success in its future endeavors. The resignation letter was signed by Company Secretary Yugandhar Kopparthi on behalf of Vivimed Labs Limited.

The company has indicated it will initiate necessary filings with stock exchanges and the Ministry of Corporate Affairs as per applicable regulations. Vivimed Labs Limited, incorporated in 1988, operates from its registered office in Kolhar Industrial Area, Bidar, Karnataka, with corporate offices in Hyderabad, Telangana.

Vivimed Labs Limited has secured significant legal relief as the Telangana High Court granted an interim stay on all Central Bureau of Investigation proceedings following search and seizure operations conducted at the pharmaceutical company's premises. The development comes after the company approached the High Court challenging the CBI actions initiated based on a State Bank of India complaint.

CBI Search and Seizure Operations

The Central Bureau of Investigation conducted search and seizure operations at Vivimed Labs' premises on 20th January, 2026. The operations were carried out by CBI's Banking Securities Fraud Branch from Bengaluru and New Delhi based on a complaint filed by State Bank of India's IFB branch in Hyderabad.

High Court Interim Relief

Vivimed Labs approached the High Court for the State of Telangana at Hyderabad seeking relief from the CBI proceedings. On 6th February, 2026, Justice Nagesh Bheemapaka granted comprehensive interim relief to the company in Writ Petition No. 1843 of 2026.

The High Court's interim order provides significant protection to Vivimed Labs by staying all further proceedings pursuant to the search and seizure operations. The court has restrained the CBI from taking any coercive steps against the company, its directors, and other stakeholders based on the search operations conducted on 20th January, 2026.

Legal Arguments and Court's Reasoning

Senior Counsel Avinash Desai, representing Vivimed Labs, argued that the search and seizure operations were based on SBI's classification of the company's account as 'fraud'. The counsel contended that this fraud declaration had been previously suspended by the court in an earlier petition (W.P.No.24697 of 2025), making the CBI's reliance on such classification inappropriate.

The High Court accepted these arguments and noted that since the fraud declaration was under suspension, the CBI should not have proceeded with coercive actions based on that classification.

Comprehensive Stay Order

The interim stay order encompasses multiple aspects of protection for Vivimed Labs. The court has restrained the CBI from taking any coercive steps based on both the search and seizure operations and SBI's complaint or fraud declaration. This comprehensive relief covers all proceedings until further orders from the High Court.

The case is scheduled for next hearing on 6th March, 2026, when the court will further examine the matter and determine the future course of action.